No Prescription |
 |
 | ||
|
Nicardia Retard SR Adalat |
|
| ||
No Prescription » Prescription Drugs 11 » Nicardia Retard SR Adalat Nifedipine is used to treat high blood pressure. It relaxes your blood vessels so your heart does not have to pump as hard. It also increases the supply of blood and oxygen to the heart to control chest pain (angina). If taken regularly nifedipine controls chest pain but it does not stop chest pain once it starts. Buy Nicardia Retard SR Adalat and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About Nicardia Retard SR Adalat: Product Type: Prescription Drugs 11 Nicardia Retard SR (Adalat Procardia Nifedecal Generic Nifedipine) Nicardia Retard SR (Adalat Procardia Nifedecal Generic Nifedipine) Adalat Procardia Nifedecal Generic Nifedipine 10mg 100 Tablets 10mg 400(2 x 200) Tablets 10mg 800(4 x 200) Tablets 20mg 200 Tablets 20mg 400(2 x 200) Tablets 20mg 800(4 x 200) Tablets Adalat Procardia Nifedecal Generic Nifedipine Nicardia Retard SR
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
